THE ROLE OF CARDIOVASCULAR IMAGING AND SERUM BIOMARKERS IN IDENTIFYING EARLY CARDIO TOXICITY RELATED TO CANCER THERAPY: NOVEL APPROACH.

Autor: TEJA, DHULIPALLA DHARMA
Předmět:
Zdroj: Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research); 2023, Vol. 14 Issue 7, p907-923, 17p
Abstrakt: Cancer therapy-related cardiac dysfunction (CTRCD) is one of the side effects that nearly one tenth of cancer patients experience. LVEF and GLS have been suggested as markers for CTRCD prediction. The timing of when strain imaging should be used to evaluate CTRCD following chemotherapy is still under investigation, but recent studies also suggest assessing cardiac biomarkers like troponin for the early detection of CTRCD. objective: The goal of this study was to find out how well echocardiography can detect CTRCD, how it relates to troponin I, and how well strain imaging can predict CTRCD one week after chemotherapy treatment. Methodology: 100 cancer patients with and without anthracycline therapy were selected for a prospective observational study from March 2019 to April 2020. Echocardiographic parameters such as LV function, GLS, GCS, and blood troponin I were evaluated prior to and one week after the start of the chemotherapeutic treatment, respectively. We used a reference range below -18 for GLS and -22 for GCS in our study to indicate significantly decreased strain. Results: Twenty-two of the 100 patients developed CTRCD. Patients who developed CTRCD had lower GLS, lower LVEF, and significantly higher troponin I levels following chemotherapeutic treatment than patients who did not develop CTRCD. GLS was strongly associated with EF in CTRCD patients (2=35.06, p 0.001) Additionally, decreased EF and GLS were significantly correlated with elevated troponin (2=31.31, p 0.001) and 78.95, respectively. Conclusion: CTRCD was linked to an increase in troponin I in a mixed cancer population. In order to predict CTRCD, the study proposes performing early strain imaging within a week of chemotherapeutic treatment. Increased troponin I was found to be significantly correlated with a decrease in strain (GLS). Early detection leads to the diagnosis of subclinical cardiac dysfunction, which improves the risk stratification of patients for chemotherapy, and treatment improves quality of life. To support the findings of this study, larger prospective studies focusing on a single type of cancer population are required. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index